Caplacizumab Brand Name– CABLIVI
What is Caplacizumab
Caplacizumab is a parenteral von Willebrand factor-directed antibody fragment indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
The efficacy of caplacizumab was established based on time to platelet count response (platelet count of 150,000/mm3 or more with discontinuation of daily plasma exchange within 5 days).
Median time to platelet count normalization was shorter with caplacizumab than with placebo (2.69 days [95% CI, 1.89 to 2.83] vs. 2.88 days [95% CI, 2.68 to 3.56], p = 0.01).
Treatment resulted in a lower number of patients with TTP-related death (0 vs. 3) and TTP recurrence (3 vs. 28). The proportion of patients with TTP recurrence in the overall study period (which included the treatment period and the 28-day follow-up period) was significantly lower in the treatment group (13%) compared to the placebo group (38%).
Caplacizumab reduced the burden of care by reducing the number of plasma exchange sessions, length of hospital stay, and length of stay in the intensive care unit.
Caplacizumab increases the risk of bleeding; severe or serious bleeding events reported in caplacizumab-treated patients included epistaxis, gingival bleeding, upper gastrointestinal bleeding, metrorrhagia, and subarachnoid hemorrhage
- thrombotic thrombocytopenia purpura
For the treatment of acquired thrombotic thrombocytopenia purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy
- antibody formation
- back pain
- GI bleeding
- injection site reaction
- vaginal bleeding
- laboratory monitoring not necessary
- dental work
- hepatic disease
No information is available regarding drug interactions associated with Caplacizumab